



First Report of DHA-1 Producing *Enterobacter cloacae* Complex Isolate in Bulgaria

Dobromira I. Dimitrova¹, Rumyana D. Markovska², Temenuga J. Stoeva¹, Petya B. Stankova², Lyudmila B. Georgieva², Kalina I. Mihova³, Radka P. Kaneva³, Ivan G. Mitov²

¹Department of Microbiology, St Marina University Hospital, Medical University, Varna, Bulgaria

²Department of Medical Microbiology, Medical University of Sofia, Sofia, Bulgaria

³Molecular Medicine Centre, Medical University of Sofia, Sofia, Bulgaria

Corresponding author: Rumyana D. Markovska, Department of Medical Microbiology, Medical University of Sofia, 1 G Sofiiski Blvd., 1431 Sofia, Bulgaria; E-mail: markovska73@abv.bg; Tel: 0359887851711

Received: 19 Nov 2018 ♦ **Accepted:** 28 Feb 2019 ♦ **Published:** 30 Sep 2019

Citation: Dimitrova DI, Markovska RD, Stoeva TJ, Stankova PB, Georgieva LB, Mihova KI, Kaneva RP, Mitov IG. First report of DHA-1 producing *Enterobacter cloacae* complex isolate in Bulgaria. Folia Med (Plovdiv) 2019;61(3):458-61. doi: 10.3897/folmed.61.e39349

The aim of the present study was to reveal the characteristics of an *Enterobacter cloacae* complex isolate producing DHA-1 AmpC enzyme recovered from a patient hospitalized in St Marina Hospital, Varna.

Materials and methods: Susceptibility testing, conjugation experiments, isoelectric focusing, PCR and sequencing were carrying out.

Results: Of 176 *Enterobacter* spp. isolates only one isolate was positive for *bla*_{DHA-1}. The sequencing revealed the presence of *bla*_{DHA-1} and *bla*_{CTX-M-3}. The antimicrobial susceptibility testing showed higher resistance rates to almost all beta-lactams (ceftazidime, cefotaxime, cefepime, amoxicillin/clavulanic acid, piperacillin/tazobactam), tobramycin, gentamycin, trimethoprim/sulphomethoxazole and quinolones (ciprofloxacin and levofloxacin). The isolate was susceptible to imipenem, meropenem and amikacin. The isoelectric focusing showed a band at pI 5.4 without ceftazidime and cefotaxime activity; a band at pI 7.8 with ceftazidime activity and another - with pI 8.4 with cefotaxime activity. Conjugation experiments were successful only for *bla*_{CTX-M-3} carrying determinants.

Conclusions: To the best of our knowledge this is the first report of DHA-1 producing isolate in Bulgaria. The emergence of DHA-1 producing *E. cloacae* complex demonstrates the possibility for further dissemination of the gene encoding this enzyme. Infectious control measures are needed for the prevention of this phenomenon.

Key words:

Bulgaria, AmpC, DHA-1, *Enterobacter cloacae* complex

INTRODUCTION

Species from *Enterobacter cloacae* complex can cause a wide range of nosocomial infections including respiratory infections, bloodstream infections (BSIs), urinary tract and surgical site infections.^{1,2} In recent years, the level of resistance towards many antibiotic groups, especially beta-lactams, has increased due to acquisition of extended-spectrum beta-lactamases (TEM-, SHV-, CTX-M-) or carbapenemases

(KPC, OXA-48, NDM).³ Additional challenges are the chromosomal class C beta-lactamases (AmpC) characteristic for *Enterobacter* spp.⁴ The treatment of infections caused by these organisms with 3rd generation cephalosporines can cause an induction of the AmpC production, which, combined with *ampD* gene mutation, can result in stable high level production of these enzymes (the strains are known as "derepressed mutants").⁴ In some cases the chromosomal AmpC gene has been mobilized on mobile elements and thus transmitted with them. Nowadays several main fam-

ilies of plasmid-mediated AmpC have been identified – CMY, DHA, FOX, MIR, ACC.⁴ The chromosomal AmpC producer could become the reservoir for plasmid-mediated enzymes, which could be easily disseminated.⁴ In Bulgaria until now only CMY-4 and AAC-1 enzymes have been reported among *Klebsiella pneumoniae* isolates.^{5,6} There are no reports on plasmid AmpC enzymes in *Enterobacter* spp. in our country. The aim of the present study was to reveal the characteristics of a DHA-1 AmpC producing *Enterobacter cloacae* complex isolate recovered from a patient hospitalized in Saint Marina Hospital – Varna.

MATERIALS AND METHODS

During a survey on ESBLs producing *Enterobacter* spp., performed in the hospital, *Enterobacter cloacae* complex isolate was recovered from the urine sample of a 47-year-old patient hospitalized in the Nephrology Ward on 21 July 2016. The patient suffered from chronic glomerulonephritis. Species level identification was done by Phoenix (Becton Dickinson, USA). Antimicrobial susceptibility testing was performed by the agar diffusion method. The results were interpreted according to the EUCAST guidelines, 2017. Conjugation experiments were carried out with rifampicin-resistant *Escherichia coli* K12:W3110 Rif R lac(-) strain, in solid cation-adjusted Mueller-Hinton agar as described previously.⁷ β -lactamases were characterized by analytical isoelectric focusing (IEF) with the laboratory prepared polyacrylamide gel with Pharmalyte pH 3.5 -9.5 (Amersham-Pharmacia), as previously described.⁷ β -lactamases bands were visualized by staining with a 500 mg/L solution of nitrocefin (BD Biosciences). Bioassay was performed to reveal the hydrolytic activity of the bands as described previously.⁷ The growth of the indicator strain identified the band with hydrolytic activity. DNA from the clinical isolate and *Escherichia coli* transconjugant were used as a template in PCR amplification. PCR experiments for beta-lactamase group detection with primers specific for ESBL (SHV, CTX-M) and plasmid-borne AmpC genes (CMY, DHA, FOX, AAC, ACT/MIR) were performed as described previously.^{7,8} The primers binding outside the genes were used for sequencing.^{7,9} The PCR amplification products were purified and directly sequenced using an ABI 3130xl Genetic Analyzer (Applied Biosystems). The sequences were compared with the reported sequences from GenBank using the Basic Local Alignment Search Tool (BLAST) program.

RESULTS

The PCR experiments for different groups of AmpC enzymes (CMY, FOX, MOX, ACC) were negative for 175 third generation cephalosporin resistant isolates of *Enterobacter* spp. Only one isolate was positive in PCR for blaDHA, as well as for blaCTX-M. The sequencing revealed the

presence of blaDHA-1 and blaCTX-M-3. The antimicrobial susceptibility of the isolate showed higher resistance rates to almost all beta-lactams (ceftazidime, cefotaxime, cefepime, amoxicillin-clavulanic acid, piperacillin/tazobactam), tobramycin, gentamicin, trimethoprim/sulphamethoxazole and quinolones (ciprofloxacin and levofloxacin). The isolate was susceptible to imipenem, meropenem and amikacin. The isoelectric focusing showed bands at: pI 5.4 without ceftazidime and cefotaxime activity (probably TEM-1 enzyme), pI 7.8 with ceftazidime activity (in this pI is focused DHA-1) and a band with pI 8.4 with cefotaxime activity (characteristic for CTX-M-3). The conjugation experiments were successful only for blaCTX-M-3 carrying determinants and the transconjugants were resistant to cefotaxime, tobramycin and gentamicin. The attempts to transfer blaDHA-1 were unsuccessful.

DISCUSSION

Laboratory detection of AmpC enzymes is important for the effective antimicrobial therapy. CMY and DHA are the most common groups of plasmid AmpC enzymes identified in *Enterobacter* spp.^{1,10-18} To the best of our knowledge this is the first report of DHA-1 producing *E. cloacae* complex isolate in Bulgaria. The isolate demonstrated multidrug resistance profile. Only carbapenems and amikacin showed preserved activity. The multiple resistance was found to be associated with DHA-1 AmpC and CTX-M-3 ESBL. Both enzymes produced bands in isoelectric focusing which confirmed their production. DHA-1 is the first member of DHA group. The number of enzymes included in this group has increased among isolates from family *Enterobacteriaceae* and is of medical concern as their production leads to treatment failure.⁴ DHA-1 enzyme was first detected in a *Salmonella enteritidis* isolate.¹⁹ It was also the first plasmid-encoded β -lactamase found to be inducible and expressed in high levels.^{4,19} DHA family enzymes have been commonly detected in *E. coli* and *K. pneumoniae*.¹⁴ DHA-1 dominated in Asian countries (Korea), and was the most common type of AmpC β -lactamase in Korea (66.6%), Japan (69%) and China 96.7%.^{16,17} There are few reports about DHA-1 positive *Enterobacter* spp. isolates.¹²⁻¹⁵

The emergence of DHA-1 producing isolates demonstrates the possibility for further dissemination of the gene encoding this enzyme. Infectious control measures are needed for the prevention of this phenomenon.

ACKNOWLEDGMENTS

The study was funded by grant No 8383/07.12.2016 and contract No. D-59/2.05.2017 from Medical University – Sofia, Bulgaria.

REFERENCES

- Davin-Regli A, Pages JM. Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment. *Front Microbiol* 2015; 6: 392.
- Mezzatesta ML, Gona F, Stefani S. Enterobacter cloacae complex: clinical impact and emerging antibiotic resistance. *Future Microbiol* 2012; 7: 887-902.
- Potter RE, D'Souza AW, Dantas G. The rapid spread of carbapenem-resistant Enterobacteriaceae. *Drug Resist Updat* 2016; 29: 30-46.
- Jacoby GA. AmpC β -lactamases. *Clin Microbiol Rev* 2009; 22: 161-82.
- Todorova B, Sabtcheva S, Ivanov IN, et al. First clinical cases of NDM-1-producing *Klebsiella pneumoniae* from two hospitals in Bulgaria. *J Infect Chemother* 2016; 22: 837-40.
- Markovska R, Schneider I, Keuleyan E, et al. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in Bulgarian hospitals. *Microb Drug Resist* 2008; 14(2): 119-12.
- Markovska R, Schneider I, Marteva-Proevska Y, et al. First detection of the AmpC beta-lactamase ACC-1 in a *Klebsiella pneumoniae* isolate in Bulgaria. *J Chemotherapy* 2012; 24(5): 307-8.
- Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated AmpC β -lactamase genes in clinical isolates by using multiplex PCR. *J Clin Microbiol* 2002; 40: 2153-62.
- Yan JJ, Ko WC, Jung YC, et al. Emergence of *Klebsiella pneumoniae* isolates producing inducible DHA-1 beta-lactamase in a university hospital in Taiwan. *J Clin Microbiol* 2002; 40(9): 3121-6.
- Bush K. Alarming β -lactamase-mediated resistance in multi-drug-resistant Enterobacteriaceae. *Curr Opin Microbiol* 2010; 13: 558-64.
- Wang S, Xiao SZ, Gu FF, et al. Antimicrobial susceptibility and molecular epidemiology of clinical Enterobacter cloacae bloodstream isolates in Shanghai, China. *PLoS One*. 2017; 12(12): e0189713.
- Harada K, Shimizu T, Mukai Y, et al. Phenotypic and molecular characterization of antimicrobial resistance in Enterobacter spp. isolates from companion animals in Japan. *PLoS One* 2017; 12(3): e0174178.
- Peymani A, Naserpour-Farivar T, Yeylagh-Beygi M, et al. Emergence of CMY-2- and DHA-1-type AmpC β -lactamases in Enterobacter cloacae isolated from several hospitals of Qazvin and Tehran, Iran. *Iran J Microbiol* 2016; 8(3): 168-74.
- Mata C, Miró E, Alvarado A, et al. Plasmid typing and genetic context of AmpC β -lactamases in Enterobacteriaceae lacking inducible chromosomal AmpC genes: findings from a Spanish hospital 1999–2007. *J Antimicrob Chemother* 2012; 67: 115-22.
- Song W, Kim JS, Kim HS, et al. Increasing trend in the prevalence of plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking chromosomal ampC gene at a Korean university hospital from 2002 to 2004. *Diagn Microbiol Infect Dis* 2006; 55: 219-24.
- Yamasaki K, Komatsu M, Abe N, et al. Laboratory surveillance for prospective plasmid-mediated AmpC beta-lactamases in the Kinki region of Japan. *J Clin Microbiol* 2010; 48: 3267-73.
- Li Y, Li Q, Du Y, et al. Prevalence of plasmid-mediated AmpC beta-lactamases in a Chinese university hospital from 2003 to 2005: first report of CMY-2-Type AmpC β -lactamase resistance in China. *J Clin Microbiol* 2008; 46: 1317-21.
- Bedenić B, Sardelić S, Luxner J, et al. Molecular characterization of class B carbapenemases in advanced stage of dissemination and emergence of class D carbapenemases in Enterobacteriaceae from Croatia. *Infect Genet Evol* 2016; 43: 74-82.
- Gaillot O, Clement C, Simonet M, et al. Novel transferable β -lactam resistance with cephalosporinase characteristics in *Salmonella enteritidis*. *J Antimicrob Chemother* 1997; 39: 85-7.

Первое сообщение об изоляте *Enterobacter cloacae* Complex в Болгарии

Добромира И. Димитрова¹, Румяна Д. Марковска², Теменуга Ж. Стоева¹, Петя Б. Станкова², Людмила Б. Георгиева², Калина И. Михова³, Радка П. Канева³, Иван Г. Митов²

¹Кафедра микробиологии, УМБАЛ „Св. Марина“, Медицинский университет, Варна, Болгария

²Кафедра медицинской микробиологии, Медицинский университет – София, София, Болгария

³Центр молекулярной медицины, Медицинский университет – София, София, Болгария

Адрес для корреспонденции:

Румяна Д. Марковска, Кафедра медицинской микробиологии, Медицинский университет – София, бул. „Георги Софийски“ № 1, 1431 София, Болгария;

E-mail: markovska73@abv.bg;

Tel: 0359887851711

Дата получения: 19 ноября 2018

Дата приемки: 28 февраля 2019

Дата публикации: 30 сентября 2019

Ключевые слова: Болгария, AmpC, DHA-1, *Enterobacter cloacae* complex

Образец цитирования:

Dimitrova DI, Markovska RD, Stoeva TJ, Stankova PB, Georgieva LB, Mihova KI, Kaneva RP, Mitov IG. First report of DHA-1 producing *Enterobacter cloacae* complex isolate in Bulgaria. *Folia Med (Plovdiv)* 2019;61(3):458-61. doi: 10.3897/folmed.61.e39349

Цель: этого исследования состояла в том, чтобы выявить характеристики изолята *Enterobacter cloacae* complex, продуцирующего фермент DHA-1 AmpC, полученного от пациента, госпитализированного в больнице „Св. Марина“, Варна.

Материалы и методы: Были проведены тесты на восприимчивость, эксперименты по конъюгации, изоэлектрическое фокусирование, ПЦР и секвенирование.

Результаты: Из 176 изолятов *Enterobacter* spp. только один изолят был положительным на *bla*_{DHA}. Секвенирование показало наличие *bla*_{DHA-1} и *bla*_{CTX-M-3}. Тестирование восприимчивости к антимикробным препаратам выявило более высокие показатели устойчивости почти ко всем бета-лактамам (ceftazidime, cefotaxime, cefepime, amoxicillin/clavulanic acid, piperacillin/tazobactam), tobramycin, gentamycin, trimethoprim/sulphomethoxazole и хинолонам (ciprofloxacin and levofloxacin). Изолят был восприимчив к imipenem, meropenem и amikacin. Изоэлектрическое фокусирование показало полосу pI 5.4 без активности ceftazidime и cefotaxime; полосу pI 7,8 с активностью sefoxitin и другую pI 8,4 с активностью cefotaxime. Эксперименты по конъюгации были успешными только для детерминант, несущих *bla*_{CTX-M-3}.

Заключение: Насколько нам известно, это первое сообщение о DHA-1, продуцирующем изолят в Болгарии. Появление DHA-1-продуцирующего *E. cloacae* complex указывает на возможность дальнейшего распространения гена, кодирующего этот фермент. Применение мер инфекционного контроля необходимо для предотвращения этого явления.